Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 701–800 of 1,044
Bamimore, M. A., Zaid, A., Banerjee, Y., Al-Sarraf, A. J., Abifadel, M., Seidah, N. G., Al-Waili, K., Al‐Rasadi, K., & Awan, Z. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.11.008 · Cited by 57
Self-citationManaging risks in drug discovery: reproducibility of published findings
Kannt, A., & Wieland, T. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1216-8 · Cited by 57
Lebeau, P. F., Al‐Hashimi, A., Sood, S. K., Lhoták, Š., Yu, P., Gyulay, G., Paré, G., Chen, S. R. W., Trigatti, B. L., Prat, A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744235 · Cited by 56
Self-citationCao, S., Xu, P., Yan, J., Liu, H., Liu, L., Cheng, L., Qiu, F., & Kang, N. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27102 · Cited by 56
Evison, B. J., Palmer, J. T., Lambert, G. C., Treutlein, H., Zeng, J., Nativel, B., Chemello, K., Zhu, Q. X., Wang, J., Teng, Y., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115344 · Cited by 57
Chen, Y. Q., Troutt, J. S., & Konrad, R. J. (2014) · Lipids · doi:10.1007/s11745-014-3895-6 · Cited by 56
Li, J., Li, S., Zhang, Y., Xu, R., Guo, Y., Zhu, C., Wu, N., Qing, P., Gao, Y., Sun, J., et al. (2015) · Medicine · doi:10.1097/md.0000000000002426 · Cited by 56
Pathway and network-based strategies to translate genetic discoveries into effective therapies
Greene, C. S., & Voight, B. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw160 · Cited by 50
Banach, M., & Penson, P. E. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvy301 · Cited by 56
Exome-Based Rare-Variant Analyses in CKD
Cameron‐Christie, S., Wolock, C. J., Groopman, E., Petrovski, S., Kamalakaran, S., Povysil, G., Vitsios, D., Zhang, M., Fleckner, J., March, R. E., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018090909 · Cited by 56
Bai, J. P. F., Earp, J. C., & Pillai, V. C. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0339-5 · Cited by 49
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 56
Roubtsova, A., Chamberland, A., Marcinkiewicz, J., Essalmani, R., Fazel, A., Bergeron, J. J., Seidah, N. G., & Prat, A. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m061952 · Cited by 55
Self-citationThe life cycle of the low-density lipoprotein receptor: insights from cellular and in-vivo studies
Wijers, M., Kuivenhoven, J. A., & van de Sluis, B. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000157 · Cited by 55
PCSK9 inhibition protects against myocardial ischemia-reperfusion injury via suppressing autophagy
Huang, G., Lu, X., Zhou, H., Li, R., Huang, Q., Xiong, X., Luo, Z., & Li, W. (2022) · Microvascular Research · doi:10.1016/j.mvr.2022.104371 · Cited by 52
CRISPR-Cas System: The Current and Emerging Translational Landscape
Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 55
PCSK9 gene mutations and low-density lipoprotein cholesterol
Wu, N., & Li, J. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.043 · Cited by 55
Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding
Gu, H.-M., Adijiang, A., Mah, M., & Zhang, D.-W. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m041129 · Cited by 50
Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform
Alonso, R., Defesche, J. C., Tejedor, D., Castillo, S., Stef, M. A., Mata, N., Enterría, P. G., Faedo, C. M., Forga, L., & Mata, P. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.01.017 · Cited by 55
Si-Tayeb, K., Idriss, S., Champon, B., Caillaud, A., Pichelin, M., Arnaud, L., Lemarchand, P., Le May, C., Zibara, K., & Cariou, B. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.022277 · Cited by 50
Dyslipidemia management update
Chang, Y., & Robidoux, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.005 · Cited by 55
Zakharova, F. M., Damgaard, D., Mandelshtam, M. Y., Golubkov, V. I., Nissen, P. H., Nilsen, G. G., Stenderup, A., Lipovetsky, B. M., Konstantinov, V. O., Denisenko, A. D., et al. (2005) · BMC Medical Genetics · doi:10.1186/1471-2350-6-6 · Cited by 55
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia
Pandit, S., Wisniewski, D., Santoro, J. C., Ha, S., Ramakrishnan, V., Cubbon, R. M., Cummings, R. T., Wright, S. D., Sparrow, C. P., Sitlani, A., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800049-jlr200 · Cited by 48
Somanathan, S., Jacobs, F., Wang, Q., Hanlon, A. L., Wilson, J. M., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.115.304008 · Cited by 54
Ginger Beer: An Overview of Health Benefits and Recent Developments
Nutakor, C., Essiedu, J. A., Adadi, P., & Kanwugu, O. N. (2020) · Fermentation · doi:10.3390/fermentation6040102 · Cited by 54
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
Gu, Y. J., Lin, X., Dong, Y., Wood, G. A., Seidah, N. G., Werstuck, G. H., Major, P. P., Bonert, M., Kapoor, A., & Tang, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02584-y · Cited by 54
Self-citationCarreau, V., Girardet, J.-P., & Bruckert, É. (2011) · Pediatric Drugs · doi:10.2165/11591650-000000000-00000 · Cited by 54
Yadav, K., Sharma, M., & Ferdinand, K. C. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.05.006 · Cited by 54
Rosei, E. A., & Salvetti, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0155-2 · Cited by 54
Di Taranto, M. D., Benito-Vicente, A., Giacobbe, C., Uribe, K. B., Rubba, P., Etxebarria, A., Guardamagna, O., Gentile, M., Martín, C., & Fortunato, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-15543-x · Cited by 45
The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
Gordts, P. L. S. M., & Esko, J. D. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.010 · Cited by 54
Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
Spolitu, S., Dai, W., Zadroga, J. A., & Ozcan, L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000601 · Cited by 46
Hallman, D. M., Srinivasan, S. R., Chen, W., Boerwinkle, E., & Berenson, G. S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.057 · Cited by 54
Junyent, M., Gilabert, R., Zambón, D., Pocoví, M., Mallén, M., Cofán, M., Núñez, I., Civeira, F., Tejedor, D., & Ros, E. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.153841 · Cited by 54
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 54
PCSK9 inhibitors in the prevention of cardiovascular disease
Latimer, J., Batty, J. A., Neely, R. D. G., & Kunadian, V. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1364-1 · Cited by 54
Genetics: A gene of rare effect
Hall, S. S. (2013) · Nature · doi:10.1038/496152a · Cited by 54
Sorrentino, V., Scheer, L., Santos, A., Reits, E., Bleijlevens, B., & Zelcer, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.249557 · Cited by 53
Butkinaree, C., Canuel, M., Essalmani, R., Poirier, S., Benjannet, S., Asselin, M.-C., Roubtsova, A., Hamelin, J., Marcinkiewicz, J., Chamberland, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.647180 · Cited by 53
Self-citationA review of PCSK9 inhibition and its effects beyond LDL receptors
Dixon, D. L., Trankle, C., Buckley, L., Parod, E., Carbone, S., Van Tassell, B. W., & Abbate, A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.07.004 · Cited by 53
microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Dong, J., He, M., Li, J., Pessentheiner, A., Wang, C., Zhang, J., Sun, Y., Wang, W.-T., Zhang, Y., Liu, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143812 · Cited by 53
Exploring the dark genome: implications for precision medicine
Oprea, T. I. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09809-0 · Cited by 50
Technological readiness and implementation of genomic‐driven precision medicine for complex diseases
Franks, P. W., Melén, E., Friedman, M., Sundström, J., Kockum, I. S., Klareskog, L., Almqvist, C., Bergen, S. E., Czene, K., Hägg, S., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13330 · Cited by 53
Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection
Zhang, X., Xu, H., Yu, J., Cui, J., Chen, Z., Li, Y., Niu, Y., Wang, S., Ran, S., Zou, Y., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.062788 · Cited by 45
Chiou, K.-R., & Charng, M. (2012) · Gene · doi:10.1016/j.gene.2012.01.092 · Cited by 53
Ly, K., Saavedra, Y. G. L., Canuel, M., Routhier, S., Desjardins, R., Hamelin, J., Mayne, J., Lazure, C., Seidah, N. G., & Day, R. W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.541094 · Cited by 53
Self-citationAung, L. H. H., Yin, R., Miao, L., Hu, X.-J., Yan, T.-T., Cao, X., Wu, D., Li, Q., Pan, S., & Wu, J. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-5 · Cited by 53
Genetic diagnosis of familial hypercholesterolemia in Han Chinese
Chiou, K.-R., & Charng, M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.01.009 · Cited by 53
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk, W., May, C. L., & Cariou, B. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.013 · Cited by 53
Fatahian, A., Haftcheshmeh, S. M., Azhdari, S., Farshchi, H. K., Nikfar, B., & Momtazi‐Borojeni, A. A. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_42 · Cited by 53
Functional characterization of splicing and ligand-binding domain variants in the LDL receptor
Etxebarria, A., Palacios, L., Stef, M., Tejedor, D., Uribe, K. B., Oleaga, A., Irigoyen, L., Torres, B., Ostolaza, H., & Martin, C. (2012) · Human Mutation · doi:10.1002/humu.21630 · Cited by 48
Slimani, A., Harira, Y., Trabelsi, I., Jomaa, W., Maatouk, F., Hamda, K. B., & Slimane, M. N. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0238-2 · Cited by 53
Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors
Krysa, J. A., Ooi, T. C., Proctor, S. D., & Vine, D. F. (2017) · Journal of Nutrition · doi:10.3945/jn.116.235069 · Cited by 53
Robinson, J. R., Denny, J. C., Roden, D. M., & Driest, S. L. V. (2017) · Clinical and Translational Science · doi:10.1111/cts.12522 · Cited by 53
Kantor, B., O’Donovan, B., Rittiner, J., Hodgson, D., Lindner, N., Guerrero, S., Dong, W., Zhang, A., & Chiba-Falek, O. (2024) · Nature Communications · doi:10.1038/s41467-024-50515-6 · Cited by 38
Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes
Yang, S., Li, S., Zhang, Y., Xu, R., Guo, Y., Zhu, C., Wu, N., Cui, C.-J., Sun, J., & Li, J. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2712 · Cited by 52
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects
Kawashiri, M., Hayashi, K., Konno, T., Fujino, N., Ino, H., & Yamagishi, M. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0391-5 · Cited by 52
Proprotein convertase subtilisin/kexin type 9 inhibition
Marais, D. A., Blom, D. J., Petrides, F., Gouëffic, Y., & Lambert, G. C. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283587563 · Cited by 52
Mining the genome for lipid genes
Kuivenhoven, J. A., & Hegele, R. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.028 · Cited by 52
Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders
Ibarretxe, D., Girona, J., Plana, N., Cabré, A., Ferré, R., Amigó, N., Guaita, S., Mallol, R., Heras, M., & Masana, L. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.11.001 · Cited by 52
Curcumin Protects Against Intestinal Origin Endotoxemia in Rat Liver Cirrhosis by Targeting PCSK9
Cai, Y., Lu, D., Zou, Y., Zhou, C., Liu, H., Tu, C., Li, F., Liu, L., & Zhang, S. (2017) · Journal of Food Science · doi:10.1111/1750-3841.13647 · Cited by 52
Leshchiner, E. S., Rush, J. S., Durney, M. A., Cao, Z., Dančík, V., Chittick, B., Wu, H., Petrone, A., Bittker, J. A., Phillips, A. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705748114 · Cited by 52
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Shapiro, M. D., Miles, J., Tavori, H., & Fazio, S. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2485 · Cited by 50
Iacocca, M. A., Wang, J., Sarkar, S., Dron, J. S., Lagace, T., McIntyre, A. D., Lau, P., Robinson, J. F., Yang, P., Knoll, J. H., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.07.479 · Cited by 46
The effect of chronic kidney disease on lipid metabolism
Dinçer, N., Dağel, T., Afşar, B., Covic, A. C., Ortíz, A., & Kanbay, M. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-2047-y · Cited by 52
Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
Schuster, S., Rubil, S., Endres, M., Princen, H. M. G., Boeckel, J., Winter, K., Werner, C. M., & Laufs, U. (2019) · Scientific Reports · doi:10.1038/s41598-019-47242-0 · Cited by 52
Identification of a PCSK9-LDLR disruptor peptide with in vivo function
Brousseau, M. E., Clairmont, K. B., Spraggon, G., Flyer, A. N., Golosov, A. A., Grosche, P., Amin, J., Andre, J., Burdick, D., Caplan, S., et al. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.08.012 · Cited by 49
Arnold, N., & Köenig, W. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01782-6 · Cited by 52
Yang, A., Gyulay, G., Mitchell, M., White, E., Trigatti, B. L., & Igdoura, S. A. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m027300 · Cited by 48
Molecular population genetics of PCSK9: a signature of recent positive selection
Ding, K., & Kullo, I. J. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f44d99 · Cited by 52
Precision annotation of digital samples in NCBI’s gene expression omnibus
Hadley, D., Pan, J., El-Sayed, O. M., Aljabban, J., Aljabban, I., Azad, T. D., Hadied, M. O., Raza, S., Rayikanti, B. A., Chen, B., et al. (2017) · Scientific Data · doi:10.1038/sdata.2017.125 · Cited by 52
Genome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 51
Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis
Taranto, M. D. D., & Fortunato, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043224 · Cited by 51
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 51
Peters, B. J. M., Pett, H., Klungel, O. H., Stricker, B. H. C., Psaty, B. M., Glazer, N. L., Wiggins, K. L., Bis, J. C., de Boer, A., & der Zee, A. H. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.023 · Cited by 51
Khoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 51
Self-citationPott, J., Schlegel, V., Teren, A., Horn, K., Kirsten, H., Bluecher, C., Kratzsch, J., Loeffler, M., Thiery, J., Burkhardt, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001992 · Cited by 48
Loaiza, N., Hartgers, M. L., Reeskamp, L. F., Balder, J.-W., Rimbert, A., Bazioti, V., Wolters, J. C., Winkelmeijer, M., Jansen, H., Dallinga‐Thie, G. M., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313470 · Cited by 51
Kukharchuk, V. V., Владиславович, Е. М., Викторович, С. И., Arabidze, G. G., Балахонова, Т. В., Gurevich, V. S., Zelveyan, P. A., Murataliev, T. M., Myrzakhmetova, G., Александровна, С. О., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-6-29 · Cited by 51
Inclisiran in lipid management: A Literature overview and future perspectives
Scicchitano, P., Milo, M., Mallamaci, R., De Palo, M., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112227 · Cited by 44
A PCSK9 variant and familial combined hyperlipidaemia
Abifadel, M., Bernier, L., Dubuc, G., Nuel, G., Rabès, J.-P., Bonneau, J., Marques, A., Marduel, M., Devillers, M., Munnich, A., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.059980 · Cited by 48
Self-citationLi, H., & Liu, J. (2012) · Biochemical Journal · doi:10.1042/bj20111645 · Cited by 46
PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling
Guan, Y., Liu, X., Yang, Z., Zhu, X., Liu, M., Du, M., Pan, X., & Wang, Y. (2025) · Circulation · doi:10.1161/circulationaha.124.072336 · Cited by 50
“10,11 At the cellular level, circulating PCSK9 binds with LDLR on cell surface and is then internalized through CCV-mediated endocytosis, similar to LDL. 12,13 In contrast to LDL, PCSK9 forms a tight complex with LDLR in an acidic endosome, leading to their final degradation in the lysosome 12–14…”
Sun, Z., Yun, Z., Lin, J., Sun, X., Wang, Q., Duan, J., Li, C., Zhang, X., Xu, S., Wang, Z., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05178-8 · Cited by 51
Zhang, Y., Liu, H., Zhen, W., Jiang, T., & Cui, J. (2025) · Carbohydrate Research · doi:10.1016/j.carres.2025.109426 · Cited by 50
Medeiros, A. M., Alves, A. C., & Bourbon, M. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.71 · Cited by 50
Familial Hypercholesterolemia: Present and Future Management
Sjouke, B., Kusters, D. M., Kastelein, J. J. P., & Hovingh, G. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0219-9 · Cited by 50
Defining the spectrum of alleles that contribute to blood lipid concentrations in humans
Kathiresan, S., Musunuru, K., & Orho‐Melander, M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f70296 · Cited by 50
Hong-mei, G., & Zhang, D. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150067 · Cited by 50
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Banerjee, Y., Santos, R. D., Al‐Rasadi, K., & Rizzo, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.018 · Cited by 50
Vaccination against atherosclerosis
Kobiyama, K., Saigusa, R., & Ley, K. F. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.008 · Cited by 50
How to live to 100 before developing clinical coronary artery disease: a suggestion
Braunwald, E. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab532 · Cited by 50
Moving toward genome-editing therapies for cardiovascular diseases
Musunuru, K. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148555 · Cited by 50
Chiou, K., & Charng, M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.01.356 · Cited by 50
Insulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
“The acyl-CoA dehydrogenases are bound to flavin adenine dinucleotide (FAD) and are reduced to FADH 2 upon dehydrogenation of acyl chains (97).”
PCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Self-citationPCSK9: an emerging target for treatment of hypercholesterolemia
Duff, C. J., & Hooper, N. M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.547480 · Cited by 49
FAM20C Overview: Classic and Novel Targets, Pathogenic Variants and Raine Syndrome Phenotypes
Lara, I. P., Pérez-Ramírez, M., Alonso-Themann, P. G., Espinosa-García, A. M., Godínez-Aguilar, R., Bonilla‐Delgado, J., López-Ornelas, A., Victoria-Acosta, G., Olguín‐García, M. G., Moreno, J. G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158039 · Cited by 49
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Stoekenbroek, R. M., Kastelein, J. J., & Huijgen, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0503-4 · Cited by 44
Roth, E. M., & Diller, P. M. (2014) · Future Cardiology · doi:10.2217/fca.13.107 · Cited by 49
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.